samedan logo
 
 
 
spacer
home > ebr > summer 2004 > beating cancer cells at their own game
PUBLICATIONS
European Biopharmaceutical Review

Beating Cancer Cells at their own Game

Cancer is a serious threat to everyone in the developed world: one in three people will suffer from the disease at some point during their lifetime, and of this number a quarter will die. Every year, more than 10 million people are diagnosed with cancer and it is estimated that by 2020 this figure will increase to 15 million new cases every year. Cancer is responsible for 12 per cent of deaths worldwide. Therefore, these statistics emphasise the growing need for safe and effective therapies for cancer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Lindy Durrant, Founder and Chief Scientific Officer at Scancell Ltd, Professor Stephen P Jackson Founder and Chief Scientific Officer at KuDOS Pharmaceuticals Ltd and Dr Klaus Giese, Chief Scientific Officer, VP Research at atugen AG

Professor Lindy Durrant is the Founder and Chief Scientific Officer at Scancell Ltd. An internationally recognised Immunologist in the field of tumour therapy, Professor Durrant has worked for 21 years in translational research, developing products for clinical trials, including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham and is currently running clinical trials in colorectal cancer and osteosarcoma.


Professor Stephen P Jackson is the Founder and Chief Scientific Officer at KuDOS Pharmaceuticals Ltd. He is a Molecular Biologist and leading expert in DNA repair and continues to conduct academic research. In 2002, he was awarded the Anthony Dipple Carcinogenesis Young Investigators' Award for his contributions to the field of molecular oncology and he has received both the Tenovus Medal and the Biochemical Society Colworth Medal. Professor Jackson has been elected to the European Molecular Biology Organisation and the Academy of Medical Sciences. He is Deputy Chairman of the Wellcome/CRUK Gurdon Institute of Cancer and Developmental Biology and is the Frederick James Quick Professor of Biology at the University of Cambridge, which was a co-founder of KuDOS Pharmaceuticals together with Cancer Research Technology.


Dr Klaus Giese is the Chief Scientific Officer, VP Research at atugen AG. He began his career as a Biochemist, Research Scientist and postdoctoral fellow at the Howard Hughes Medical Institute, University of California, San Francisco, and subsequently at the Max-Planck Institute for Molecular Genetics in Berlin. Prior to joining atugen, Dr Giese was Group Leader at Chiron Corporation, Emeryville, CA from 1994 to 1998 and was responsible for co-ordinating and managing part of Chiron's obesity and oncology programme. His efforts in this programme included the development of several different gene expression profiling approaches and the development of a novel high-throughput screening assay to identify inhibitors of HIV-1 transcription.

spacer
Professor Lindy Durrant
spacer
spacer
spacer
Professor Stephen P Jackson
spacer
spacer
spacer
Dr Klaus Giese
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform

 Dundee, UK, 14th December 2021 – Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement